Last reviewed · How we verify

IV Abatacept

Rüdiger B. Müller · FDA-approved active Small molecule

IV Abatacept is a T-cell costimulation inhibitor Small molecule drug developed by Rüdiger B. Müller. It is currently FDA-approved for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis. Also known as: Switch from SC to IV Abatacept and back.

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.

At a glance

Generic nameIV Abatacept
Also known asSwitch from SC to IV Abatacept and back
SponsorRüdiger B. Müller
Drug classT-cell costimulation inhibitor
TargetCD80/CD86
ModalitySmall molecule
Therapeutic areaImmunology
PhaseFDA-approved

Mechanism of action

Abatacept (CTLA4-Ig) acts as a selective costimulation modulator that interrupts the second signal required for full T-cell activation. By binding to CD80 and CD86 molecules on antigen-presenting cells, it prevents interaction with CD28 on T cells, effectively suppressing the adaptive immune response. This mechanism makes it particularly useful in autoimmune conditions where T-cell-mediated inflammation drives disease pathology.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IV Abatacept

What is IV Abatacept?

IV Abatacept is a T-cell costimulation inhibitor drug developed by Rüdiger B. Müller, indicated for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.

How does IV Abatacept work?

Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.

What is IV Abatacept used for?

IV Abatacept is indicated for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis, Ankylosing spondylitis, Systemic lupus erythematosus.

Who makes IV Abatacept?

IV Abatacept is developed and marketed by Rüdiger B. Müller (see full Rüdiger B. Müller pipeline at /company/r-diger-b-m-ller).

Is IV Abatacept also known as anything else?

IV Abatacept is also known as Switch from SC to IV Abatacept and back.

What drug class is IV Abatacept in?

IV Abatacept belongs to the T-cell costimulation inhibitor class. See all T-cell costimulation inhibitor drugs at /class/t-cell-costimulation-inhibitor.

What development phase is IV Abatacept in?

IV Abatacept is FDA-approved (marketed).

What are the side effects of IV Abatacept?

Common side effects of IV Abatacept include Infection (upper respiratory, urinary tract), Headache, Nausea, Dizziness, Hypertension, Serious infections.

What does IV Abatacept target?

IV Abatacept targets CD80/CD86 and is a T-cell costimulation inhibitor.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing